Skip to content
MRD Watch

Wednesday, November 18, 2026

Subscribe
Sponsor this briefing. One site and newsletter slot, $250/week.

Briefing

MiRaDE: ctDNA minimal residual disease after prostatectomy for high-risk prostate cancer

Pilot cohort study of a prostate-specific ctDNA panel to estimate how often minimal residual disease is detected six weeks after radical prostatectomy and how that result relates to early distant relapse.

Radboud University Medical Center